Key Highlights
- Christof Marré joins as Senior Vice President and Head of Commercial.
- Steven Shiff, M.D., appointed as SVP, Clinical Research.
- Jack Kyte promoted to SVP, Human Resources.
- Focus on pivotal Phase 3 RESTORATiVE303 trial for C. difficile and Phase 2 COLLECTiVE202 trial for ulcerative colitis.
Source: Business Wire
Notable Quote
- “I am delighted to welcome Christof and Steve to the team. The expertise that Christof, Steve, and Jack bring are vital to our next phase of growth as we execute our ongoing pivotal Phase 3 RESTORATiVE303 trial of VE303 for C. difficile infection and Phase 2 COLLECTiVE202 trial of VE202 for ulcerative colitis, and establish our commercial function.” — Bernat Olle, Ph.D., Co-Founder and CEO at Vedanta Biosciences
SoHC's Take
Vedanta Biosciences is poised for significant growth with the strategic appointments of Christof Marré, Steven Shiff, M.D., and the promotion of Jack Kyte. Marré’s extensive background in biopharma marketing and commercial strategy, combined with Dr. Shiff’s profound expertise in gastroenterology and clinical development, will bolster the company’s efforts in advancing their crucial clinical trials. Kyte’s leadership in human resources will ensure the organization’s internal and external alignment with its ambitious goals. These appointments underscore Vedanta’s commitment to leveraging top-tier talent to drive innovation and success in the biopharmaceutical sector.
